What is Canndoc?
Headquartered in Herzliya, Israel, Canndoc operates as a cornerstone of the InterCure ecosystem, specializing in the end-to-end lifecycle of pharmaceutical-grade cannabis. The company maintains a robust portfolio that includes the research, cultivation, production, and distribution of medical-grade dried inflorescences and oil-based extracts. By adhering to stringent pharmaceutical standards, Canndoc has successfully positioned itself as a leader in the Israeli market while simultaneously expanding its reach into international territories. Beyond its core cannabis operations, the firm actively participates in the broader biomed sector, leveraging its expertise to identify and invest in high-potential healthcare innovations that align with its mission of improving patient outcomes through specialized therapeutic products.
How much funding has Canndoc raised?
Canndoc has raised a total of $18M across 1 funding round:
Other Financing Round
$18M
Other Financing Round (2024): $18M, investors not publicly disclosed
Key Investors in Canndoc
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Canndoc?
With the recent influx of capital, Canndoc is well-positioned to accelerate its strategic objectives, particularly regarding the optimization of its supply chain and the expansion of its clinical research initiatives. The company is expected to focus on scaling its production capabilities to meet the rising global demand for standardized medical cannabis products. Furthermore, the integration of this financing will likely support the firm's ongoing efforts to navigate complex regulatory environments in new markets, ensuring that its pharmaceutical-grade offerings remain accessible to patients worldwide. As Canndoc continues to mature, its dual focus on operational excellence and strategic biomed investments will be pivotal in maintaining its competitive advantage in an evolving healthcare industry.
See full Canndoc company page
